Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 2,426 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Predictive Oncology Inc | POAI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.08 | 4.82% | 1.74 | 08:47:40 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.66 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 31 | 2,426 | - | 1.12 - 7.12 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:20:09 | 1 | $ 1.71 | USD |
Predictive Oncology Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 6.74M | 4.06M | - | 1.78M | -13.98M | -3.44 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Predictive Oncology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical POAI Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.25 | 1.85 | 1.12 | 1.40 | 112,044 | 0.49 | 39.20% |
| 1 Month | 2.62 | 2.62 | 1.12 | 1.57 | 54,702 | -0.88 | -33.59% |
| 3 Months | 3.01 | 3.76 | 1.12 | 2.23 | 33,890 | -1.27 | -42.19% |
| 6 Months | 3.00 | 3.76 | 1.12 | 2.57 | 25,229 | -1.26 | -42.00% |
| 1 Year | 3.08 | 7.12 | 1.12 | 3.73 | 61,911 | -1.34 | -43.51% |
| 3 Years | 21.20 | 32.80 | 1.12 | 16.87 | 780,275 | -19.46 | -91.79% |
| 5 Years | 11.62 | 107.80 | 1.12 | 22.40 | 959,819 | -9.88 | -85.03% |
Predictive Oncology Description
| Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response. |
